ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ono Pharmaceutical Co., Ltd. ?
1
High Management Efficiency with a high ROE of 12.49%
2
Company has very low debt and has enough cash to service the debt requirements
3
With ROE of 6.41%, it has a very attractive valuation with a 0.97 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 62.17%, its profits have fallen by -62%
- At the current price, the company has a high dividend yield of 0
4
Majority shareholders : FIIs
5
Market Beating Performance
- The stock has generated a return of 62.17% in the last 1 year, much higher than market (Japan Nikkei 225) returns of 38.59%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Ono Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ono Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ono Pharmaceutical Co., Ltd.
-100.0%
0.41
25.52%
Japan Nikkei 225
38.59%
1.45
26.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.73%
EBIT Growth (5y)
-4.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.57
Tax Ratio
15.48%
Dividend Payout Ratio
75.08%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
20.45%
ROE (avg)
12.49%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
0.97
EV to EBIT
10.81
EV to EBITDA
7.59
EV to Capital Employed
0.96
EV to Sales
1.41
PEG Ratio
NA
Dividend Yield
0.03%
ROCE (Latest)
8.91%
ROE (Latest)
6.41%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-22What is not working for the Company
NET PROFIT(HY)
At JPY 11,044 MM has Grown at -73.85%
INTEREST(HY)
At JPY 3,232 MM has Grown at 4,209.33%
OPERATING CASH FLOW(Y)
Lowest at JPY 85,019 MM
ROCE(HY)
Lowest at 5.41%
RAW MATERIAL COST(Y)
Grown by 5.16% (YoY
PRE-TAX PROFIT(Q)
Fallen at -32%
Here's what is working for Ono Pharmaceutical Co., Ltd.
Depreciation
Highest at JPY 9,238 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Ono Pharmaceutical Co., Ltd.
Net Profit
At JPY 11,044 MM has Grown at -73.85%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Interest
At JPY 3,232 MM has Grown at 4,209.33%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Operating Cash Flow
Lowest at JPY 85,019 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (JPY MM)
Pre-Tax Profit
Fallen at -32%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (JPY MM)
Raw Material Cost
Grown by 5.16% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
